8 names are moving together; 63% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| BCDA | BioCardia, Inc. | Healthcare | -10.0% | 1/7 observed active sessions |
| VERU | Veru Inc. | Healthcare | -8.9% | Group member |
| CLNN | Clene Inc. | Consumer Defensive | +1.8% | 3/7 observed active sessions |
| RXRX | Recursion Pharmaceuticals, Inc. | Healthcare | +1.5% | 2/7 observed active sessions |
| ABCL | AbCellera Biologics Inc. | Healthcare | +3.5% | Group member |
| PACB | Pacific Biosciences of Californ | Healthcare | +0.3% | Group member |
| DNA | Ginkgo Bioworks Holdings, Inc. | Healthcare | -0.1% | 1/7 observed active sessions |
| TEM | Tempus AI, Inc. | Healthcare | +5.0% | Group member |
Cohort
8 namesParticipation
63% this sessionObserved history
59 daily buildsFiling coverage
8/8 membersproduct pipeline / R&D affecting expense
“Research and development expenses decreased to approximately $1.2 million in the three months ended March 31, 2026 as compared to approximately $1.5 million in the three months ended March 31, 2025, primarily due to closeout of the CardiAMP Heart Failure Trial, partially offset by early enrollment in the CardiAMP Heart Failure II Trial and regulatory activities to advance CardiAMP in Japan.”
BCDA 10-Q
restructuring affecting expense
“Through December 31, 2025, there have been no such impairment losses. (j) Clinical Trial Accruals As part of the process of preparing our consolidated financial statements, we are required to estimate our expenses resulting from our obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials.”
BCDA 10-K
restructuring
“If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.”
BCDA 10-K
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
TEMcustomer · Current intraday read unavailable
Filing receipt · AZN / TEM
“We issued a warrant to our customer AstraZeneca in conjunction with the signing of the MSA in November 2021.”
TEM · customer
RXRXinvestee · Current intraday read unavailable
Filing receipt · RLYB / RXRX
“Pursuant to the Purchase Agreement, we acquired 50% of the issued and outstanding membership interests (the “Membership Interests”) of RE Ventures I, LLC (“ENPP1 JV”) fr…”
RXRX · investee
TEMpartner · Current intraday read unavailable
Filing receipt · PSNL / TEM
“We also have a collaboration with Tempus that enables Tempus to market our NeXT Personal ® Dx test to physicians for breast cancer, lung cancer, colorectal cancer and im…”
TEM · partner
DNApartner · Current intraday read unavailable
Filing receipt · SYBX / DNA
“Our transactions with Genomatica and Synlogic included the purchase of equity securities and the provision of R&D services.”
DNA · partner
PACBtext peer · Current intraday read unavailable
No filing excerpt is available for this relationship.